PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapsjspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS J. 2006 March; 8(1): E65–E75.
Published online 2006 February 24. doi:  10.1208/aapsj080108
PMCID: PMC3889506

Current status of immunologic approaches to treating tobacco dependence: Vaccines and nicotine-specific antibodies

Abstract

In contrast to current pharmacotherapies, immunologic approaches to treating tobacco dependence target the drug itself rather than the brain. This approach involves the use of nicotine-specific antibodies that bind nicotine in serum, resulting in a decrease in nicotine distribution to the brain and an increase in nicotine's elimination half-life. This review summarizes the literature examining the effects of immunologic interventions on the pharmacokinetics and behavioral effects of nicotine in animal models, as well as recent phase I and II clinical trials in humans. Studies using various vaccines and nicotine-specific antibodies in rodents have shown that immunization can significantly reduce the behavioral effects of nicotine that are relevant to tobacco dependence (eg, nicotine self-administration). These findings provide proof of principle that immunologic interventions could have utility in the treatment of tobacco dependence. Thus far, phase I clinical trials of nicotine vaccines have not produced any serious adverse events in humans and have produced dose-dependent increases in serum antibody levels. Although preliminary data from these small trials suggest that vaccination can facilitate abstinence from tobacco use, more advance trials are needed. By acting outside the nervous system, immunologic approaches are less likely to produce the adverse side effects associated with current medications. In addition, the unique mechanism of action of immunotherapy makes it particularly suitable for combination with other pharmacological approaches. Taken together, the work completed to date provides substantial evidence that immunologic interventions could play an important role in future treatment strategies for tobacco dependence.

Full Text

The Full Text of this article is available as a PDF (194K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
[1.] Centers for Disease ControlPrevention CDC. Annual smokingattributable mortality, years of potential life lost, and economic costs— United States, 1995–1999. MMWR Morb Mortal Wkly Rep. 2002;51:300–303. [PubMed]
[2.] U. S. Department of Health and Human Services Healthy People 2010. With understanding and improving health and objectives for improving health. Washington, DC: US Department of Health and Human Services; 2000.
[3.] Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl). 2004;175:134–142. doi: 10.1007/s00213-004-1818-6. [PubMed] [Cross Ref]
[4.] Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl). 1995;117:2–10. doi: 10.1007/BF02245088. [PubMed] [Cross Ref]
[5.] Corrigall WA. Nicotine self-administration in animals as a dependence model. Nicotine Tob Res. 1999;1:11–20. doi: 10.1080/14622299050011121. [PubMed] [Cross Ref]
[6.] Gerrits MA, Petromilli P, Di Westenberg H C ^, van Ree JM. Decrease in basal dopamine levels in the nucleus accumbens shell during daily drug-seeking behaviour in rats. Brain Res. 2002;924:141–150. doi: 10.1016/S0006-8993(01)03105-5. [PubMed] [Cross Ref]
[7.] Wonnacott S, Sidhpura N, Balfour DJ. Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol. 2005;5:53–59. doi: 10.1016/j.coph.2004.12.002. [PubMed] [Cross Ref]
[8.] Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care. 2000;45:1200–1262. [PubMed]
[9.] Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract. 2003;57:224–230. [PubMed]
[10.] Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA. 1994;271:1940–1947. doi: 10.1001/jama.1994.03510480064036. [PubMed] [Cross Ref]
[11.] Hurt RD, Sachs DP, Glover ED. A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202. doi: 10.1056/NEJM199710233371703. [PubMed] [Cross Ref]
[12.] Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2004;3:11–18. doi: 10.1586/14760584.3.1.11. [PubMed] [Cross Ref]
[13.] Pentel PR, Keyler DE. Vaccines to treat drug addiction. In: MM L, JB K, R R, MA L, MF G, editors. New Generation Vaccines. New York, NY: Marcel Dekker; 2004.
[14.] Goldberg SR, Spealman RD. Suppression of behavior by intravenous injections of nicotine or by electric shocks in squirrel monkeys: effects of chlordiazepoxide and mecamylamine. J Pharmacol Exp Ther. 1983;224:334–340. [PubMed]
[15.] Benowitz NL, Perez-Stable EJ, Herrera B, Jacob Pr. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst. 2002;94:108–115. doi: 10.1093/jnci/94.2.108. [PubMed] [Cross Ref]
[16.] Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005;77:145–158. doi: 10.1016/j.clpt.2004.10.011. [PubMed] [Cross Ref]
[17.] Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004;14:615–626. doi: 10.1097/00008571-200409000-00006. [PubMed] [Cross Ref]
[18.] Hieda Y, Keyler DE, Vandevoort JT. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther. 1997;283:1076–1081. [PubMed]
[19.] de Villiers SH, Lindblom N, Kalayanov G. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration. 2002;69:247–253. doi: 10.1159/000063628. [PubMed] [Cross Ref]
[20.] Carrera MR, Ashley JA, Hoffman TZ. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem. 2004;12:563–570. doi: 10.1016/j.bmc.2003.11.029. [PubMed] [Cross Ref]
[21.] Sanderson SD, Cheruku SR, Padmanilayam MP. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol. 2003;3:137–146. doi: 10.1016/S1567-5769(02)00260-6. [PubMed] [Cross Ref]
[22.] Cerny EH, Levy R, Mauel J. Preclinical development of a vaccine “against smoking.” Onkologie. 2002;25:406–411. doi: 10.1159/000067433. [PubMed] [Cross Ref]
[23.] Pentel PR, Malin DH, Ennifar S. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav. 2000;65:191–198. doi: 10.1016/S0091-3057(99)00206-3. [PubMed] [Cross Ref]
[24.] Maurer P, Jennings GT, Willers J. A therapeutic vaccine for nicotine dependence: preclinical effi cacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35:2031–2040. doi: 10.1002/eji.200526285. [PubMed] [Cross Ref]
[25.] LeSage MG, Keyler DE, Hieda Y. Psychopharmacology (Berl). 2005. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine selfadministration in rats; pp. 1–8. [PubMed]
[26.] Meijler MM, Jr, Matsushita M, Jr, Altobell L, Jr, Wirsching P, Janda KD. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc. 2003;125:7164–7165. doi: 10.1021/ja034805t. [PubMed] [Cross Ref]
[27.] St Clair Roberts J, Akers CVR, Vanhinsbergh L, McKenna KA, Wood DM, Jack L. Longitudinal safety and immunogenicity data of TA-NIC, a novel nicotine vaccine. New Orleans, LA. Middletown, WI: Society for Research on Nicotine and Tobacco; 2003.
[28.] Hatsukami D, Rennard S, Jorenby DE. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456–467. doi: 10.1016/j.clpt.2005.08.007. [PubMed] [Cross Ref]
[29.] St Clair Roberts J, Dobson J, Wood D, Settles M. Safety and immunogenicity of a human nicotine conjugate vaccine. Drug Alcohol Depend. 2002;66:S148.
[30.] Keyler DE, Roiko SA, Benlhabib E. Monoclonal nicotinespecifi c antibodies reduce nicotine distribution to brain in rats: doseand affinity-response relationships. Drug Metab Dispos. 2005;33:1056–1061. doi: 10.1124/dmd.105.004234. [PubMed] [Cross Ref]
[31.] Malin DH, Lake JR, Lin A. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav. 2001;68:87–92. doi: 10.1016/S0091-3057(00)00436-6. [PubMed] [Cross Ref]
[32.] de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:299–304. doi: 10.1007/s00210-004-0960-3. [PubMed] [Cross Ref]
[33.] Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol. 2003;3:957–970. doi: 10.1016/S1567-5769(03)00094-8. [PubMed] [Cross Ref]
[34.] Perkins KA, Jacobs L, Sanders M, Caggiula AR. Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology (Berl). 2002;163:194–201. doi: 10.1007/s00213-002-1168-1. [PubMed] [Cross Ref]
[35.] Keyler DE, Hieda Y, St Peter J, Pentel PR. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res. 1999;1:241–249. doi: 10.1080/14622299050011361. [PubMed] [Cross Ref]
[36.] Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000;22:809–819. doi: 10.1016/S0192-0561(00)00042-4. [PubMed] [Cross Ref]
[37.] Keyler DE, Dufek MB, Calvin AD. Reduced nicotine distribution from mother to fetal brain in rats vaccinated against nicotine: time course and influence of nicotine dosing regimen. Biochem Pharmacol. 2005;69:1385–1395. doi: 10.1016/j.bcp.2005.02.007. [PubMed] [Cross Ref]
[38.] Stolerman IP. Interspecies consistency in the behavioural pharmacology of nicotine dependence. Behav Pharmacol. 1999;10:559–580. doi: 10.1097/00008877-199911000-00002. [PubMed] [Cross Ref]
[39.] Tuncok Y, Hieda Y, Keyler DE. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol. 2001;9:228–234. doi: 10.1037/1064-1297.9.2.228. [PubMed] [Cross Ref]
[40.] Shiffman S, West R, Gilbert D, SRNT Work Group on the Assessment of CravingWithdrawal in Clinical Trials Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res. 2004;6:599–614. doi: 10.1080/14622200410001734067. [PubMed] [Cross Ref]
[41.] Malin DH, Alvarado CL, Woodhouse KS. Passive immunization against nicotine attenuates nicotine discrimination. Life Sci. 2002;70:2793–2798. doi: 10.1016/S0024-3205(02)01523-0. [PubMed] [Cross Ref]
[42.] Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002;69:254–260. doi: 10.1159/000063629. [PubMed] [Cross Ref]
[43.] Keyler DE, Shoeman D, LeSage MG, Calvin AD, Pentel PR. Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J Pharmacol Exp Ther. 2003;305:587–592. doi: 10.1124/jpet.102.046805. [PubMed] [Cross Ref]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists